

**S. 369, the Preserve Access to Affordable Generics Act, As Reported by the Senate Judiciary Committee on October 15, 2009**

Fiscal year, in millions of dollars

Updated June 16, 2010

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2010 - 2015	2010 - 2020
<b>Direct Spending</b>													
Budget Authority	0	-170	-170	-180	-150	-130	-130	-270	-360	-420	-440	-800	-2,420
Outlays	0	-170	-170	-180	-150	-130	-130	-270	-360	-420	-440	-800	-2,420
<b>Revenues</b>													
Revenue Effects	0	15	15	25	25	25	25	25	30	30	45	105	260
<i>On-budget</i>	0	10	10	20	20	20	20	20	20	20	30	80	190
<i>Off-budget</i>	0	5	5	5	5	5	5	5	10	10	15	25	70
<b>Net Decrease in the Deficit</b>													
Net Impact on the Unified Deficit a/	0	-185	-185	-205	-175	-155	-155	-295	-390	-450	-485	-905	-2,680
<i>On-budget</i>	0	-180	-180	-200	-170	-150	-150	-290	-380	-440	-470	-880	-2,610
<i>Off-budget</i>	0	-5	-5	-5	-5	-5	-5	-5	-10	-10	-15	-25	-70

Source: Congressional Budget Office

Note: The original estimate for this bill was sent on January 28, 2010. This estimate has been updated to reflect the passage of the Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Reconciliation Act of 2010 (P.L. 111-151), and to reflect the 2010 - 2020 time period; the original estimate reflected the 2010 - 2019 period.

a. Negative numbers indicate reductions in the deficit.